Saturday, July 11, 2026

pharma · IC - Interstitial Cystitis · Interstitial Cystitis · LIPO

LIPELLA PHARMACEUTICALS

Lipella Pharmaceuticals is a pharma organization headquartered in Pittsburgh, USA. It trades on NYSE under ticker LIPO. Primary therapeutic focus areas include IC - Interstitial Cystitis, Interstitial Cystitis, Hemorrhag

Pittsburgh, USA HQ
2005 Founded
3 Employees
Public company Type
LIPO · NYSE Ticker
Company details
Status
Public
HQ
Pittsburgh, USA
Founded
2005
Employees
3
Programs
4
Drugs
3
Patents
4
Clinical program

LP-10

Phase 2 · small molecule · Hemorrhagic Cystitis

LP-10 for Hemorrhagic Cystitis is a Phase 2 program (small_molecule) at LIPELLA PHARMACEUTICALS INC. with 1 ClinicalTrials.gov record(s).

← All LIPELLA PHARMACEUTICALS INC. projects Phase 2 small molecule completed

Internal code Safety and Efficacy of LP-10

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
LIPELLA PHARMACEUTICALS INC.
Phase
Phase 2
Modality
small_molecule
Indication
Hemorrhagic Cystitis
Status
completed
Trials
1

Clinical trials